Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

STRATA Skin Sciences (SSKN) Accumulated Expenses (2016 - 2025)

STRATA Skin Sciences' Accumulated Expenses history spans 15 years, with the latest figure at $1.9 million for Q4 2025.

  • On a quarterly basis, Accumulated Expenses fell 74.02% to $1.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.9 million, a 74.02% decrease, with the full-year FY2025 number at $1.9 million, down 74.02% from a year prior.
  • Accumulated Expenses hit $1.9 million in Q4 2025 for STRATA Skin Sciences, down from $6.2 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for SSKN hit a ceiling of $7.6 million in Q3 2024 and a floor of $63000.0 in Q1 2021.
  • Historically, Accumulated Expenses has averaged $3.3 million across 5 years, with a median of $2.0 million in 2021.
  • Biggest five-year swings in Accumulated Expenses: surged 5085.05% in 2021 and later plummeted 97.86% in 2022.
  • Tracing SSKN's Accumulated Expenses over 5 years: stood at $2.1 million in 2021, then dropped by 2.68% to $2.0 million in 2022, then soared by 215.77% to $6.3 million in 2023, then increased by 16.78% to $7.4 million in 2024, then plummeted by 74.02% to $1.9 million in 2025.
  • Business Quant data shows Accumulated Expenses for SSKN at $1.9 million in Q4 2025, $6.2 million in Q3 2025, and $5.9 million in Q2 2025.